The Health Care System in US: Overview and Challenges

Some how They are above copy write and patent law; that states that an individual/company can hold exclusive rights for only three years to regain research and development costs and make some profit. This was established so companies/individuals could not establish a monopoly on a product/service letting them completely control the market price. This is some thing that in the rest of the civilized democratic countries is not allowed and drug are part of the free market system. An example of this would be in Canada the same U.S. Company sells its drugs cheaper to compete with prices in the open market and in the U.S. they charge more money because of their monopoly on the drug.

U.S. based companies hold rights to most of the world’s rights on new medicines and holds thousands of new products currently being developed. As of 2012, the industry helps support almost 3.4 million jobs in the U.S. economy. It is also one of the most heavily R&D based industries in the world. In the United States, the environment for pharmaceuticals is much friendlier than other countries around the world in terms of pricing ability and regulations. Both the Pharmaceutical and Biotechnology industries have experienced significant growth in the past year with year-over-year increases of 13.02% and 34.69% respectively. It is an even more striking when looking at the past five years considering both have beat out the S&P 500 with pharmaceuticals increasing an additional 31.44% and the biotechnology sector besting an astonishing 269.3% more return than the

United States is the richest country in the world, yet when it comes to the health care of its

In the U.S., the Patient Protection and Affordable Care Act, authorized the FDA to approve generic versions of biologic drugs and grant drug manufacturers 12 years of exclusive use before generics can be developed. The FDA law offers PharmaCARE a 180 day exclusivity period to generic drug manufacturers in specific cases. Only one generic manufacturer can produce the generic version of a drug during the exclusivity period. This exclusivity period is only used when a generic manufacturer argues that a patent is invalid or is not violated in the generic production of a drug, and the period acts as a reward for the generic manufacturer who is willing to risk liability in court and the cost of patent court litigation. There is often contention around

The U.S healthcare system is considered one of the most expensive in the world. Financing the U.S healthcare system can be put into payments made by the government, private groups of individuals, and the consumer. Single payer refers to a way of financing health care, which includes both the collection of money for health care and reimbursement of providers for healthcare costs. In the United States, there are multiple payers, not a single payer. Single payer does not specify a health care delivery mechanism; it specifies a health care financing mechanism. The system must provide health care for mostly all residents regardless of age, employment, income, or health status, even though there are some limited exceptions. But in the end the

The United States health care system is one that gets considered to give proper medical attention in the region. It is a system that developed through initiatives presented by the private sectors which give an enormous amount of funds. In comparison with other countries in the world; it is the United States that spends more money on health care when calculated per person (Thomas, 2016). The literature indicates that its percentage has a larger margin close to 53% when get compared to the nearest country which is Norway. For example, when narrowed down to the district of Colombia, the amount of money that the state spends ranges between $5000 to $1000.

In the United States, both U.S. Patent Law and U.S. “ Food and Drug Administration” (FDA) law govern the exclusivity rights for new pharmaceutical products. As Chinese companies invest research time and money in developing new drugs, it is important to keep in mind both the relevant U.S. patent law and the applicable FDA law that could affect the exclusivity period for that drug in the United States. Mistakes in not obtaining proper patent coverage or satisfying the FDA laws could cost the drug company valuable exclusivity rights when that drug is sold in the United States. For a successful drug, the lost of exclusivity rights usually means the loss of substantial revenue and profit.

Patents on drugs are in the interests of the sick as well as the industry. Protection should not be weakened

While this case is literally full of negative aspects, we will only focus on the main points for both arguments. Pharmaceutical companies want to be sure that the products they spend years and millions of dollars to create are not easily reproduced and sold at discount prices. The profits pharmaceuticals make of their patented products are supposed to refinance new research. So taking away their exclusive distribution rights and allowing other manufacturers to just copy the product and sell it at

The Doha round’s trade negotiations over intellectual property have been long and arduous. After more than a decade there is still no agreement over the extent of patent protection that should be afforded to pharmaceuticals. The shadow of the future adds additional complications, as the involved parties have no reason to settle now, when they can wait and hope for more favorable terms in the future. Despite this looming threat, the future holds promise for a drug access settlement. As technology improves and trade agreements become more ubiquitous, it will create a larger zone of agreement between the parties, making it easier to settle the dispute.

Companies-producers of “blockbusters” are in an advantageous position because drugs that fall into this category provide faster and deeper penetration into the market due to their excellent properties and patent protection. Launch of a “blockbuster” guarantees high sales to the company. However, those companies face a number of difficulties associated with the entry of generics after the expiration of patent protection. First, sales of the original product plunge. Consequently, companies have to reduce their prices to compete.

Just think about it, if all the pharmaceutical scientist are not willing to research and develop new drugs in medicines field, all of the disease will cannot be control even include infectious virus will spread to entire world, then it will become very terrible and serious problem. Therefore, carry out the extend of medicine patent protection is very important.

The purpose of the patent system is to encourage innovations by ensuring that they are protected and utilized in a way that contributes to the development of industries, and to promote technological innovation and dissemination of technology (John and Wendy 1). Patent laws are territorial in nature and are not enforceable to another country from which they were not issued unless there is separate patent applications filed in those countries. However, when it comes to protecting medical drugs, the patent system becomes a controversial issue, and this majorly relates to the provision of drugs in developing countries.

The availability of patents for pharmaceutical products has been a huge controversy in the patent system over the years. The reason for this is that the necessary operating licenses of which the inventor will benefit cost an amount of money which maybe developing countries will not be able to afford. There are two approaches to follow in this debate, the legal side in which the law must be followed and the human side, in which the needs of people are taken into account regardless of other things. These two options lead to a question: should the patentability of pharmaceutical products be excluded in order to protect the right to health of those who can not pay these products?

Cipla should look to protect their patents on particular medications and explains why rules governing intellectual property rights in industrialized nations should not apply to poorer countries.